18 August 2026
18 August 2026
Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.
After completion of the merger, the combined company will develop Slate’s migraine treatment pipeline.
The designation applies to those who have previously undergone platinum-based chemotherapy and an immune checkpoint inhibitor.
This new guidance provides doctors in the UK with another important treatment option for heart failure (HF).
Discover how GSK, Boehringer Ingelheim, Takeda and more than 100 pharma leaders scale digital projects at AUTOMA+ 2026 in Switzerland.
Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
